Showing results (761-770 of 993) with videos related to

Sort By:
Pageof 100
Psychological Reports|June 3, 2020
A Parallel Process Model of Integration and Multidimensional Prosocial Behaviors in Recent Immigrant U.S. Latinx AdolescentsMeredith McGinley, Alexandra N Davis, Gustavo Carlo, et al.
Science Immunology|September 2, 2022
Embryonic and neonatal waves generate distinct populations of hepatic ILC1sColin Sparano, Darío Solís-Sayago, Anjali Vijaykumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupAmye J Tevaarwerk, Molin Wang, Fengmin Zhao, et al.
Blood Advances|December 22, 2018
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomasErin G Reid, David Looney, Frank Maldarelli, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2022
Azathioprine therapy induces selective NK cell depletion and IFN-γ deficiency predisposing to herpesvirus reactivationFlorian Ingelfinger, Colin Sparano, David Bamert, et al.
Journal of the National Cancer Institute|January 18, 2012
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trialJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamideJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Cancer Treatment Reviews|March 6, 2025
Current controversies in the use of Oncotype DX in early breast cancerPier Paolo M Berton Giachetti, Ambra Carnevale Schianca, Dario Trapani, et al.
Eclinicalmedicine|December 2, 2024
Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic reviewSusanne Osanto, Anne-Laurien van de Vliert-Bout, Cristina Alvarez Gomez de Segura, et al.
Pageof 100